Top 50 Personalized Medicine in Europe

The startup provides a Smart Medicine solution that employs real-time data analytics and machine learning algorithms to create personalized treatment plans based on individual patient profiles and medical histories. This approach enhances medication accuracy and efficiency, addressing the limitations of traditional healthcare systems.

Curenetics utilizes an AI-powered platform that integrates genomics, imaging, and clinical data to predict individual patient responses to cancer therapies. This technology addresses the high variability in treatment effectiveness, enabling personalized treatment plans that improve patient outcomes and reduce unnecessary healthcare costs.

STALICLA utilizes a precision neuro medicine platform that combines multiomics, patient data, and AI to match individuals with neurodevelopmental disorders to tailored pharmacological treatments. The company focuses on addressing the biological complexity of conditions like Autism Spectrum Disorder, aiming to improve patient outcomes through personalized medicine.

dehaze integrates medical AI models into clinical workflows to enhance diagnostic accuracy and prognostic capabilities tailored to individual patient data. This approach addresses the limitations of standardized treatment guidelines by providing personalized healthcare solutions based on unique health profiles.

Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.

The startup employs microbiome analysis to assess the interactions between gut bacteria and pharmaceuticals, enabling personalized drug efficacy evaluations for individual patients. This method provides specific insights into how a patient's unique microbiome profile influences their response to medications.

The startup develops personalized cancer immunotherapy that identifies optimal neoantigens to target and activate T-lymphocytes for the precise elimination of cancer cells. This approach aims to enhance patient recovery by tailoring treatments to individual tumor profiles, improving efficacy in cancer management.

Zoī is a personalized preventive medicine application that utilizes data science and behavioral science to analyze routine medical checkup data, providing tailored lifestyle recommendations to enhance health and longevity. The platform includes ongoing support from preventive care specialists, ensuring users implement these recommendations effectively to improve their quality of life.

Celsius Therapeutics develops precision medicines utilizing genomic and proteomic data to create targeted therapies for patients with cancer and autoimmune diseases. By focusing on the underlying biological mechanisms of these conditions, the company aims to improve treatment efficacy and patient outcomes.

IMU Biosciences utilizes systems-level immunophenotyping and machine learning analytics to map the immune system, generating over 2,000 discrete cell subset profiles. This technology enables precise disease modeling and drug development, facilitating advancements in personalized immune medicine.

Navignostics utilizes spatial single-cell proteomics and multiplex protein imaging to analyze tumor samples, enabling precise identification of optimal therapies for individual cancer patients. This approach enhances personalized diagnostics and accelerates drug development by providing critical insights into tumor characteristics and drug mechanisms for clinicians and pharmaceutical partners.

Genomate Health develops a computational platform that utilizes artificial intelligence to analyze the unique molecular profiles of cancer patients' tumors, enabling oncologists to identify the most effective targeted therapies. This approach improves treatment outcomes by providing data-backed recommendations that consider multiple genetic alterations, significantly increasing the likelihood of positive patient responses.

WellMe.ai utilizes a functional and integrative approach to health by employing precision wellness methods, including comprehensive health assessments and personalized protocols based on genetic and metabolic testing. The platform addresses the challenges of conventional medicine by providing tailored solutions for optimizing healthspan, managing chronic conditions, and enhancing overall well-being through a dedicated team of health practitioners.

The startup develops a machine platform that integrates silicon chip technology with microfluidic processing for the large-scale manufacturing of personalized cell therapies. This technology enables real-time control and manipulation of cellular processes, providing cost-effective and safe treatments tailored for individual cancer patients.

The startup operates a personal health and genomic data-sharing platform that connects users with researchers, enabling participation in studies on common and rare diseases. By allowing individuals to control their data and opt into research, the platform facilitates the collection of dynamic health and genetic datasets for personalized medicine.

Doppl operates a crowd-sourced biobank that collects biological samples from citizen donors to facilitate personalized medicine and drug development. The company specializes in engineering organoid models for preclinical drug testing, addressing the need for relevant and scalable disease models in medical research.

YGION Biomedical develops personalized cancer vaccines that utilize neoantigen-based immunotherapy to trigger tumor-specific immune responses by harnessing the patient's own immune system. This approach aims to improve treatment efficacy and minimize side effects, enhancing the quality of life for cancer patients.

Closed Loop Medicine develops personalized digital healthcare solutions that integrate dose-optimized drug therapy with digital therapeutics to enhance treatment adherence and patient outcomes. The platform addresses the inefficiencies of traditional healthcare delivery, which often leads to suboptimal management of chronic conditions and increased costs for payors.

Spotlight Medical develops AI-driven prognosis tests that utilize extensive patient data to enhance treatment selection for cancer care. The company addresses the challenge of inadequate treatment options by providing personalized insights into each patient's unique disease profile, aiming to improve outcomes and increase the likelihood of remission.

TrueYouOmics utilizes DNA, RNA, and protein analyses, combined with AI-driven algorithms, to extract up to 3 billion datapoints from blood samples for personalized health risk assessments. The platform provides users with specific disease risk evaluations and tailored prevention plans, empowering them to make informed health decisions.

Theremia utilizes an AI-driven platform to enhance drug efficacy and minimize side effects by tailoring treatments to the specific needs of diverse patient demographics. The company improves clinical trial processes, leading to more precise outcomes and faster market access for pharmaceutical products.

One Biosciences utilizes single-cell technologies and AI-driven analysis to create high-resolution omics profiles of tumors, enabling precise patient selection and treatment strategies. This approach addresses the complexity of advanced cancer biology, facilitating the development of targeted therapeutics for difficult-to-treat diseases.

Mosaic Therapeutics develops targeted drug combinations for cancer treatment by utilizing genome-scale CRISPR screening and advanced computational models to identify effective therapies based on the molecular characteristics of tumors. The company addresses the challenge of cancer's complexity and heterogeneity, aiming to improve patient outcomes through precision medicine in biomarker-defined settings.

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

Strike Pharma develops individualized immunotherapeutic treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology, which targets tumor cells based on the genetic profile of each patient's tumor. This approach enhances therapeutic efficacy while minimizing side effects, addressing the limitations of traditional immunotherapy methods that often overlook efficient drug delivery and stability.

NU offers a modular multi-omics digital health platform that integrates genetic, epigenetic, and microbiome data to generate personalized health insights and actionable recommendations. This technology enables health practitioners to efficiently manage client data and create tailored health plans, ultimately enhancing client outcomes and optimizing aging processes.

Holifya provides at-home DNA and blood analysis services, enabling users to monitor genetic markers and essential health parameters. The platform offers personalized nutrition and prevention plans, supported by certified medical professionals, to help individuals optimize their health based on their unique biological data.

TwinEdge Bioscience provides a cloud‑based platform that creates high‑fidelity digital twins of individual patient tumors by integrating genomics, transcriptomics, proteomics and histopathology data. Its AI‑augmented simulation engine predicts drug response, resistance mechanisms and biomarker associations across a library of over 10,000 validated tumor avatars, enabling pharmaceutical and CRO teams to prioritize candidates, design trials and stratify patients before human enrollment.

GenomeKey utilizes advanced genomic sequencing technology to analyze genetic data for personalized medicine applications. The company provides insights that enhance treatment efficacy and reduce adverse drug reactions, improving patient outcomes in healthcare.

The company utilizes mass spectrometry imaging and machine learning algorithms for high-resolution proteomic profiling to characterize tumors in oncology. This approach enables personalized treatment plans for patients with poor prognosis cancers, improving patient management and reducing healthcare costs.

Protyon develops molecular modeling tools that create three-dimensional digital representations of cancer mutations, enabling precise predictions of drug interactions and treatment efficacy. This technology allows clinicians to select the most effective therapies for individual patients, improving treatment outcomes and reducing the costs associated with ineffective treatments.

The startup develops AI-powered precision medicine technology that utilizes multi-omics analysis to decode cellular health and identify molecular causes of diseases. This approach enhances early disease detection and enables targeted therapies for non-invasive prenatal and oncology testing.

Cytocast provides a digital twin platform for simulating molecular interactions within human cells to predict drug efficacy and side effects. By integrating multi-omics and patient-specific data, the platform accelerates drug discovery and development by enabling _in silico_ testing and personalized medicine insights.

Cellink develops advanced 3D bioprinters and bioinks for the precise fabrication of human tissues, enabling researchers to create patient-specific models for personalized medicine and drug discovery. Their technology addresses the need for more physiologically relevant models in biomedical research, enhancing the understanding of human biology and accelerating therapeutic development.

Phenomics Health is a bioinformatics platform that integrates genomic and phenotypic data to create personalized treatment plans for patients. The platform enhances therapeutic outcomes by providing insights tailored to individual biological profiles, addressing the inefficacy of standard treatment approaches.

NEC OncoImmunity AS utilizes proprietary machine learning algorithms to predict neoantigen presentation and immunogenicity, enabling the development of personalized immunotherapies for cancer patients. The company's technology enhances the selection of patient-specific targets in immuno-oncology clinical trials, improving treatment outcomes.

The startup specializes in precision oncology by employing targeted therapies and immunotherapies tailored to the genetic profiles of individual tumors. This method enhances treatment efficacy while reducing side effects for various cancer types.

Melio Bio develops precision medicines for cardiometabolic diseases by translating human genetic insights into novel therapeutic strategies. The company identifies and validates genetic targets to create more effective treatments for conditions like diabetes, obesity, and cardiovascular disorders.

Normax Biomed develops personalized mRNA cancer immunotherapies that utilize neoantigen targeting to train the immune system to specifically attack a patient's unique cancer cells. This approach addresses the limitations of traditional treatments by minimizing side effects and improving long-term survival rates for individuals living with cancer.

RootPath Genomics develops a personalized T cell therapy platform utilizing molecular programming-based DNA fragment assembly technology to provide researchers with scalable access to long synthetic genes and their functional readouts. This approach addresses the need for efficient gene function interrogation in precision medicine, enabling faster and more accurate therapeutic development.

Oncolines provides precision medicine services for oncology and immunotherapy through bioinformatics analysis, gene mutation profiling, and tissue sensitivity testing. The company enables the identification of patient selection markers and the development of targeted therapies, facilitating faster access to effective treatments for specific patient populations.

This startup utilizes machine learning algorithms to provide personalized diagnoses, prognoses, and treatment plans, enhancing the accuracy of patient care. By transforming traditional statistical methods into tailored solutions, it addresses the need for individualized healthcare experiences and improved patient outcomes.

Provides a personalized medicine platform that combines functional medicine, lab testing, and lifestyle data to identify and treat the root causes of chronic conditions such as gut disorders, weight management, hormonal imbalances, and mental health issues. Patients receive tailored treatment plans that integrate online medical consultations, nutrition, health coaching, and Traditional Chinese Medicine, with over 80% of users reporting symptom improvement within two months.

Axia Medicine provides a platform that empowers patients to manage and control their health data, facilitating personalized healthcare solutions tailored to individual needs. By enabling secure access and sharing of health information, the platform enhances patient engagement and improves health outcomes.

Kuma Health utilizes personalized medicine to provide tailored treatment plans for individuals with autoimmune diseases, enhancing patient outcomes and quality of life. The platform addresses the lack of effective, individualized care options in autoimmune disease management, enabling patients to better manage their conditions.

VIVAN Therapeutics utilizes the Personal Discovery Process to replicate a patient's genetic profile and screen up to 500,000 drug combinations using engineered fruit fly avatars. This approach addresses the challenge of drug resistance in cancer treatment by identifying effective multi-drug therapies tailored to the unique mutations of each patient's tumor network.

The startup develops medical software that utilizes in silico modeling and computer simulations to enhance personalized medicine. By providing healthcare professionals with detailed insights and data, the application enables safer and more effective personalized treatments and diagnostics for patients.

The startup develops AI-powered, biomarker-guided solutions that utilize patented protein design and an automated biomarker device to enhance the targeted delivery of RNA and protein therapeutics. This technology enables precise treatment for patients by ensuring that therapies are delivered to the appropriate cells, improving therapeutic efficacy and patient outcomes.

The startup operates a biomarker discovery platform that utilizes artificial intelligence and genomic analysis techniques to identify personalized cancer therapies for patients. This approach enhances patient stratification, enabling healthcare providers to deliver more effective treatment options tailored to individual needs.

The startup provides transparent AI technology that enhances tissue-based diagnostics and prognostics in computational pathology. By integrating with existing workflows, it improves disease treatment efficiency in clinical and pharmaceutical settings, enabling personalized medicine through effective AI utilization.